AMD, Soft Drusen, Reticular Pseudodrusen, Drusen Stage Macular Degeneration, Drusen (Degenerative) of Macula, Bilateral
Conditions
Keywords
postbiotic, vitamins, drusen, intermediate AMD
Brief summary
A pilot study to establish the efficacy and safety of supplementation with postbiotics in patients with macular degeneration.
Interventions
DIETARY_SUPPLEMENTPostbotics and Vitamins
2 capsule 3 times a day, before meals
DIETARY_SUPPLEMENTVitamins
2 capsule 3 times a day, before meals
Sponsors
Igen BioLab SLU
Institut de la Macula y la Retina
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects of either gender aged 50 years or older with high risk intermediate AMD defined as the following criteria: \>4 areas of at least iRORA or iORA (incomplete RPE and outer retinal atrophy and incomplete outer retinal atrophy). 1 area of cRORA + 2 \> areas of iRORA. \< 1 mm2 of cRORA (complete RPE and outer retinal atrophy). No exudative neovascular AMD.
Exclusion criteria
Best corrected visual acuity in the study eye less than 20/400 by ETDRS. Not ability to provide written informed consent. Not ability to return for all trial visits. if subject cannot attend all trial required visits. GA secondary to any condition other than specified. Any ocular condition in the study eye that would progress during the study that could affect central vision or otherwise be a confounding factor. Concomitant treatment with any ocular or systemic medication that is known to be toxic to the lens, retina or optic nerve. Anti -VEGF therapy is allowed in Cohort B. Presence of intraocular inflammation (≥ trace cell or flare), macular hole, pathologic myopia, epiretinal membrane, evidence of significant vitreo-retinal traction maculopathy, vitreous hemorrhage or aphakia (pseudophakia with or without an intact capsule is not an
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Microperimetry | 12 months | Median change difference in the % reduced threshold in microperimetry |
| Color vision change | 12 months | Median change in red/green and yellow/blue color thresholds |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Low luminance visual acuity (LLVA) | 12 months | Mean Change of Low luminance visual acuity (LLVA) |
| Rod and cone sensitivity | 12 months | Mean change of Rod and cone sensitivity test |
| Advanced Vision and Optometric Test (AVOT) | 12 months | Mean change AVOT vision test |
| incomplete retinal pigment epithelial and outer retinal atrophy (iRORA) conversion loci | 12 months | Number of scans within the optical coherence tomography OCT cube as as per protocol (Spectralis OCT cube protocol: 20º x 20ª, 97b-scan, high-resolution, 62 microns between scans centered at the fovea) with features of iRORA2 conversion loci (change from baseline to 12 months of iRORA loci). |
| complete retinal pigment epithelial and outer retinal atrophy (cRORA) conversion loci | 12 months | Number of scans within the OCT cube as as per protocol with of features of cRORA (change from baseline to 12 months of cRORA loci). |
| Area of cumulative cRORA conversion | 12 months | Area of cumulative cRORA conversion as measured in mm2 by en face OCT projection scans of the OCT cube as as per protocol |
| Average Threshold microperimetry | 12 months | Mean change of Average Threshold microperimetry |
| Change in outer nuclear layer (ONL) volume | 12 months | Change in outer nuclear layer (ONL) volume measured by the spectralis software after manually correction of the layer segmentation |
| Change of drusen > 100 microns height | 12 months | Change of number of drusen of \> 100 microns height measured by OCT within the OCT cube as as per protocol |
| Change of subretinal drusenoid deposits (SDD) through ellipsoid zone (ELZ) | 12 months | Change of number of subretinal drusenoid deposits (SDD) through ellipsoid zone within the OCT cube as as per protocol |
| Change of SDD ribbon | 12 months | Change of number SDD ribbon within the OCT cube as as per protocol |
| Conversion to choroidal neovascularization (CNV) | 12 months | Any conversion to any type of macular neovascularization (MNV) within the OCT cube as as per protocol 1 as per OCT features of leakage, and/or intrarretinal, subretinal or subRPE fluid, and/or presence of Subretinal hyperreflective material(SHRM) |
| Hyperreflective dots(HRD)+ (retinal pigment epithelium)RPE defects areas conversion | 12 months | Number of scans within the OCT cube as as per protocol with HRD+RPE defects areas conversion (change from baseline to 12 months of HRD+RPE defects) |
| Best corrected visual acuity (BCVA) | 12 months | Mean Change of Best corrected visual acuity (BCVA) |
Countries
Spain
Contacts
Primary ContactJordi Mones, MD PhD
Backup ContactMiriam Garcia, OD, MSc
Outcome results
None listed